Varespladib Methyl (LY-333013; A-002; S-3013) is a novel and potent sPLA2 (secretory phospholipase A2) inhibitor with the potential for treating acute coronary syndrome (ACS). It is an orally bioavailable prodrug of varespladib, which inhibits the IIA, V and X isoforms of sPLA2 to reduce inflammation, lower and modulate lipid levels, and reduce levels of C-reactive protein (CRP) and interleukin-6 (IL-6), both indicators of inflammation.

纯度：≥98%

CAS：172733-08-3